These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 16186073)

  • 21. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application.
    Mueck AO; Genazzani AR; Samsioe G; Vukovic-Wysocki I; Seeger H
    Menopause; 2007; 14(6):978-84. PubMed ID: 17595593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testosterone addition to estrogen therapy - effects on inflammatory markers for cardiovascular disease.
    Kocoska-Maras L; Hirschberg AL; Byström B; Schoultz BV; Rådestad AF
    Gynecol Endocrinol; 2009 Dec; 25(12):823-7. PubMed ID: 19906002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of continuation of postmenopausal hormone replacement therapy: transdermal versus oral estrogen.
    Ettinger B; Pressman A; Bradley C
    Menopause; 1998; 5(3):152-6. PubMed ID: 9774760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women.
    Ichikawa J; Sumino H; Ichikawa S; Ozaki M
    Am J Hypertens; 2006 Jul; 19(7):744-9. PubMed ID: 16814131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No increase in C-reactive protein levels during intranasal compared to oral hormone therapy in healthy post-menopausal women.
    Hemelaar M; Kenemans P; Schalkwijk CG; Braat DD; van der Mooren MJ
    Hum Reprod; 2006 Jun; 21(6):1635-42. PubMed ID: 16501036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
    Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
    Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased risk of recurrent venous thromboembolism during hormone replacement therapy--results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET).
    Høibraaten E; Qvigstad E; Arnesen H; Larsen S; Wickstrøm E; Sandset PM
    Thromb Haemost; 2000 Dec; 84(6):961-7. PubMed ID: 11154141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of high dose oestrogen therapy on circulating inflammatory markers.
    Wilson R; Spiers A; Ewan J; Johnson P; Jenkins C; Carr S
    Maturitas; 2009 Mar; 62(3):281-6. PubMed ID: 19231116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women.
    Ho JY; Chen MJ; Sheu WH; Yi YC; Tsai AC; Guu HF; Ho ES
    Hum Reprod; 2006 Oct; 21(10):2715-20. PubMed ID: 16807281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article.
    Lakoski SG; Herrington DM
    Climacteric; 2005 Dec; 8(4):317-26. PubMed ID: 16390766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of hormone replacement therapy on glucose and lipid profiles and on cardiovascular risk parameters in postmenopausal women.
    Bingol B; Gunenc Z; Yilmaz M; Biri A; Tiras B; Güner H
    Arch Gynecol Obstet; 2010 May; 281(5):857-64. PubMed ID: 19593578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of hormone replacement therapy on endothelial function in postmenopausal women with hypertension.
    Czarnecka D; Kawecka-Jaszcz K; Olszanecka A; Dembińska-Kieć A; Malczewska-Malec M; Zdzienicka A; Guevara I
    Med Sci Monit; 2004 Feb; 10(2):CR55-61. PubMed ID: 14737044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of long-term transdermal hormone replacement therapy on the renin-angiotensin- aldosterone system, plasma bradykinin levels and blood pressure in normotensive postmenopausal women.
    Ichikawa A; Sumino H; Ogawa T; Ichikawa S; Nitta K
    Geriatr Gerontol Int; 2008 Dec; 8(4):259-64. PubMed ID: 19149837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study.
    Collins P; Flather M; Lees B; Mister R; Proudler AJ; Stevenson JC;
    Eur Heart J; 2006 Sep; 27(17):2046-53. PubMed ID: 16899475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Continuation of postmenopausal hormone replacement therapy in a large health maintenance organization: transdermal matrix patch versus oral estrogen therapy.
    Ettinger B; Pressman A
    Am J Manag Care; 1999 Jun; 5(6):779-85. PubMed ID: 10538456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy.
    de Maat MP; Madsen JS; Langdahl B; Bladbjerg EM; Tofteng CL; Abrahamsen B; Rejnmark L; Brixen K; Christensen K; Jespersen J; Kristensen SR
    Thromb Haemost; 2007 Feb; 97(2):234-9. PubMed ID: 17264952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
    Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of hormone replacement therapy on insulin resistance and platelet function tests.
    Saraç F; Saydam G; Sahin F; Oztekin K; Saygili F; Tüzün M; Yilmaz C
    Med Princ Pract; 2009; 18(1):43-7. PubMed ID: 19060490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation.
    Eilertsen AL; Qvigstad E; Andersen TO; Sandvik L; Sandset PM
    Maturitas; 2006 Oct; 55(3):278-87. PubMed ID: 16713143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of the central effects of different progestins used in hormone replacement therapy.
    Cagnacci A; Arangino S; Baldassari F; Alessandrini C; Landi S; Volpe A
    Maturitas; 2004 Aug; 48(4):456-62. PubMed ID: 15283939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.